Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752922 | 0.97 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16878503 | 0.94 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31247892 | 0.93 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25815434 | 0.93 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27547601 | 0.91 | — | — | |
| SCHEMBL14543103 | 0.89 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15095887 | 0.89 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11245 | 0.89 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12700286 | 0.89 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16878211 | 0.89 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698280-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | Synaffix B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| EP-4620982-A1 | PREGELATINIZED HYDROPHILICALLY MODIFIED LEGUME STARCH WITH INCREASED HYDROPHOBICITY AND ITS USES AS A WATER-RESISTANT FILM FORMER | ROQUETTE FRERES (FR) | 2025-09-24 | — | — | EP | disclosed |
| US-20250281383-A1 | NON-THERAPEUTIC USE OF HYPERBRANCHED DEXTRINS AS A SOOTHING AGENT | ROQUETTE FRERES (FR) | 2025-09-11 | — | — | US | disclosed |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2025-08-21 | — | — | US | disclosed |
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-12290593-B2 | Butter preparation process | Naturochim (FR) | 2025-05-06 | — | — | US | disclosed |
| US-12226379-B2 | Highly sustainable compositions for modulation of gene expression in human skin, and methods of production thereof | Visolis, Inc. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250017844-A1 | COMPOSITIONS COMPRISING A PLANT EXTRACT CONTAINING POLYGODIAL AND COSMETIC AND/OR DERMATOLOGICAL USES THEREOF | ROBERTET SA (FR) | 2025-01-16 | — | — | US | disclosed |
| US-20150141667-A1 | CATALYSTS FOR HYDRODEOXYGENATION OF OXYGENATED HYDROCARBONS | VIRENT, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8946458-B2 | Catalysts for hydrodeoxygenation of oxygenated hydrocarbons | VIRENT, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2014028723-A1 | IMPROVED CATALYSTS FOR HYDRODEOXYGENATION OF OXYGENATED HYDROCARBONS | VIRENT, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20140051872-A1 | CATALYSTS FOR HYDRODEOXYGENATION OF OXYGENATED HYDROCARBONS | VIRENT, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2496682-A1 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056935-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-1006098-A2 | Cross-bridged cyclohexane derivatives and liquid crystal medium | MERCK PATENT GmbH (DE) | 2000-06-07 | — | — | EP | disclosed |
| US-5703059-A | Disaccharide ligands for selectins | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0680487-A1 | DISACCHARIDE LIGANDS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017084-A1 | DISACCHARIDE LIGANDS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | CHRM2 1838/4885CHRM4 1889/4885CHRM5 2239/4885 |
| US-20140051872-A1 | CATALYSTS FOR HYDRODEOXYGENATION OF OXYGENATED HYDROCARBONS | HAO2, HPD, PDK1 | CHRM2 2076/4885CHRM4 1470/4885CHRM5 1407/4885 |
| US-20250017844-A1 | COMPOSITIONS COMPRISING A PLANT EXTRACT CONTAINING POLYGODIAL AND COSMETIC AND/OR DERMATOLOGICAL USES THEREOF | CUTA, PGA5, PGAM1 | CHRM2 3692/4885CHRM4 4491/4885CHRM5 4289/4885 |
| US-20150141667-A1 | CATALYSTS FOR HYDRODEOXYGENATION OF OXYGENATED HYDROCARBONS | HAO2, HPD, PDK1 | CHRM2 2076/4885CHRM4 1470/4885CHRM5 1407/4885 |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | C1S, APOL1, BTN3A1 | CHRM2 530/4885CHRM4 959/4885CHRM5 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.